newsfilter.io

APMD

  1. GlobeNewswire

    Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027 If approved, Oxnimbi has the ...

  2. GlobeNewswire

    Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed" or the "Company"), a late stage clinical pharmaceutical company dedicated to the discovery, development and ...

  3. Analyst Upgrades

    LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

    LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed with a Outperform rating and announces Price Target of $50. ...

  4. Analyst Upgrades

    This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

    Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks. ...

  5. Analyst Upgrades

    Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

    Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed with a Overweight rating and announces Price Target of $60. ...

  6. Analyst Upgrades

    Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating

    Evercore ISI Group analyst Umer Raffat initiates coverage on Apnimed with a Outperform rating. ...

  7. Analyst Upgrades

    B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41

    B of A Securities analyst Jason Gerberry initiates coverage on Apnimed with a Buy rating and announces Price Target of $41. ...

  8. GlobeNewswire

    Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel ...